查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1630996

美國口服固態劑型契約製造市場：市場規模、佔有率及趨勢分析（按產品、機制、最終用途、國家及細分市場，2025-2030 年）

U.S. Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Mechanism (Immediate Release, Delayed Release), By End Use, By Country And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國固態口服劑型契約製造市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，美國口服固態劑量契約製造市場規模預計到 2030 年將達到 164.3 億美元，2025 年至 2030 年的複合年成長率為 6.1%。該市場的成長得益於該國醫藥外包的增加和技術進步等因素。以患者為中心的劑型的需求隨著時間的推移而增加，並且由於其提高了藥物依從性，已成為醫療保健領域的一個重要趨勢。因此，製造商正在生產優先考慮易於吞嚥的口服劑型。

為了使固態口服藥物更容易獲得，製藥贊助商正在創新地將藥物製成微型或迷你片劑或噴霧膠囊。這種配方方法越來越受歡迎，尤其是在兒童和老年人中。慢性病和感染疾病的日益普及也是推動新型療法需求的一個主要因素。此外，老年人口的不斷成長導致慢性病發病率上升，進一步推動了對新治療過程的需求。

現有藥物的不良反應也增加了對新治療方法的需求。例如，根據利物浦大學 2022 年 7 月發表的一項研究，因副作用相關的住院率從 2004 年的 6.5% 上升到 2019 年的 16.5%。對現有治療產生不良反應的病例不斷增加，預計將推動未來對新治療的需求。

創新和臨床速度是許多生物製藥公司的關鍵因素。小型公司和專業生物製藥公司越來越依賴滿足產業內的這些關鍵要求。許多 CRO 和 CDMO 都將自己定位為「一站式服務公司」。一站式服務是一種服務模式，其中 CRO 負責處理從原料藥到配方、從早期開發到商業化的所有事務。為了提供此類服務，CDMO 必須擁有廣泛的實行技術和專業能力來解決特定的問題。

此外，主要企業日益增多的策略性舉措也有望推動美國口服固態劑量 (OSD)契約製造市場的成長。例如，2023年1月，Catalent與Ethicann達成合作，利用Catalent的Zydis口溶錠(ODT)技術開發Ethicann的臨床藥物管線。再例如，2023年3月，龍沙宣佈在其菲斯普工廠全面運作新的臨床和商業藥品製造生產線。此次擴張預計將增強該公司的藥物輸送服務（DPS）。

美國口服固態製劑契約製造市場：概覽

  • 根據產品類型，錠劑領域在 2024 年佔據最高的市場佔有率。這是因為錠劑廣泛可用、易於生產且患者接受度高。
  • 預計未來幾年膠囊市場將出現顯著成長。在一個膠囊中配製具有不同釋放特性的多種藥理成分的能力推動了其需求。
  • 基於機制，控釋將在 2024 年佔據市場主導地位。控釋機制具有多種優勢，包括提高功效和安全性、減少給藥頻率和穩定血中濃度。
  • 根據最終用途，大型企業部門將在 2024 年佔據市場主導地位。契約製造製造商通常能夠根據需求波動增加或減少生產量。對於面臨 OSD 產品需求波動的大型製藥企業來說，這種彈性是一種優勢。
  • 預計未來幾年小型企業將以顯著的成長速度發展。中小企業的資金資源往往有限。擁有自己的製造工廠的建設和營運成本可能太高。合約製造可為您提供最先進的生產能力，且無需大量的前期投資。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第 3 章美國口服固態劑型契約製造市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTLE分析

第 4 章美國口服固態劑型契約製造市場：按產品分類的業務分析

  • 按產品市場佔有率（2024 年和 2030 年）
  • 產品儀表板
  • 依產品分類的市場規模預測及趨勢分析（2018-2030）
  • 錠劑
  • 膠囊
  • 粉末
  • 顆粒
  • 其他

第 5 章美國口服固態劑型契約製造市場：按機制分類的業務分析

  • 按機制分類的市場佔有率（2024 年和 2030 年）
  • 機制儀表板
  • 依機制分類的市場規模預測及趨勢分析（2018-2030）
  • 即時發布
  • 延遲釋放
  • 控釋

第6章美國口服固態劑型契約製造市場：依最終用途分類的業務分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 最終用途儀表板
  • 按最終用途分類的市場規模預測和趨勢分析（2018-2030 年）
  • 大型企業
  • 中小型企業
  • 其他

第7章 競爭格局

  • 市場參與企業概況
  • 公司市場地位分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Catalent, Inc（Novo Holdings A/S）
    • Lonza
    • AbbVie Inc.
    • Aenova Group
    • Adare Pharma Solutions
    • Boehringer Ingelheim International GmbH
    • Jubilant Pharmova Limited
    • Patheon Pharma Services（Thermo Fisher Scientific Inc.）
    • Recipharm AB
    • CordenPharma
    • Siegfried Holding AG
Product Code: GVR-4-68040-122-8

U.S. Oral Solid Dosage Contract Manufacturing Market Growth & Trends:

The U.S. oral solid dosage contract manufacturing market size is expected to reach USD 16.43 billion by 2030, registering a CAGR of 6.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing pharmaceutical outsourcing and technological advancements in the country. The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence. Consequently, manufacturers are producing oral dosage forms that prioritize ease of swallowing.

To render solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs into micro or mini tablets and sprinkle capsules. This formulation approach is gaining popularity, especially among the pediatric and geriatric populations. The growing prevalence of chronic and infectious diseases is one of the major factors responsible for the rising demand for novel therapies. Furthermore, the growing geriatric population is contributing to the rising incidence of chronic diseases, further supporting the demand for novel treatment processes.

Adverse drug reactions to existing drugs are also contributing to the demand for novel treatment options. For instance, in July 2022, research published by the University of Liverpool stated that adverse drug reaction-related hospital admissions increased from 6.5% in 2004 to 16.5% in 2019. A rise in the number of cases involving adverse drug reactions to existing therapies is expected to boost the demand for new therapies in the future.

For many biopharmaceutical companies, innovations and speed-to-clinic factors are of critical importance. Small companies and specialty biopharmaceutical players increasingly rely upon delivering these important requirements within the industry. Many CROs and CDMOs promote themselves as one-stop-shop companies. The one-stop-shop service model is where a CRO handles everything from API to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities to address specific problem statements.

Furthermore, increasing undertaking of strategic initiatives by key players is also expected to drive U.S. oral solid dosage (OSD) contract manufacturing market growth. For instance, in January 2023, Catalent and Ethicann collaborated to develop Ethicann's clinical drug pipeline using Catalent's orally disintegrating tablet (ODT) technology 'Zydis'. In another instance, in March 2023, Lonza announced that its new clinical and commercial drug product manufacturing line at its Visp site had become fully operational. The expansion is expected to strengthen the company's Drug Product Services (DPS) offering.

U.S. Oral Solid Dosage Contract Manufacturing Market Report Highlights:

  • Based on product type, the tablets segment captured the highest market share in 2024.This is attributed to their widespread use, ease of manufacturing, and strong patient acceptance rate.
  • The capsule segment is expected to show significant market growth in the coming years. Multiple pharmacological ingredients with various release characteristics can be combined in capsules, thus driving their demand.
  • Based on the mechanism, the controlled release segment dominated the market in 2024. The controlled release mechanism offers multiple advantages, such as improved efficacy and safety, reduced dosage frequency, and steady blood levels.
  • Based on the end-user, the large companies segment dominated the market in 2024. Contract manufacturers generally have the capacity to scale production up or down based on requirement fluctuation. This flexibility can be advantageous for large pharma companies that experience varying levels of demand for their OSD products.
  • Medium- and small-sized companies are expected to advance at a significant growth rate in the coming years. Financial resources are frequently limited for small- and medium-sized companies. Their own manufacturing facilities might be too expensive to build and operate. They can gain cutting-edge production capabilities through contract manufacturing without making a large initial investment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mechanism
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Oral Solid Dosage Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Oral Solid Dosage Contract Manufacturing Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Tablets
    • 4.4.1. Tablets Market, 2018 - 2030 (USD Million)
  • 4.5. Capsules
    • 4.5.1. Capsules Market, 2018 - 2030 (USD Million)
  • 4.6. Powders
    • 4.6.1. Powders Market, 2018 - 2030 (USD Million)
  • 4.7. Granules
    • 4.7.1. Granules Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Business Analysis

  • 5.1. Mechanism Market Share, 2024 & 2030
  • 5.2. Mechanism Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Mechanism, 2018 to 2030 (USD Million)
  • 5.4. Immediate Release
    • 5.4.1. Immediate Release Market, 2018 - 2030 (USD Million)
  • 5.5. Delayed Release
    • 5.5.1. Delayed Release Market, 2018 - 2030 (USD Million)
  • 5.6. Controlled Release
    • 5.6.1. Controlled Release Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Oral Solid Dosage Contract Manufacturing Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Large Size Companies
    • 6.4.1. Large Size Companies Market, 2018 - 2030 (USD Million)
  • 6.5. Medium & Small Size Companies
    • 6.5.1. Medium & Small Size Companies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Catalent, Inc (Novo Holdings A/S)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Lonza
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. AbbVie Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Aenova Group
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Adare Pharma Solutions
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Boehringer Ingelheim International GmbH
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Jubilant Pharmova Limited
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Patheon Pharma Services (Thermo Fisher Scientific Inc.)
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Recipharm AB
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. CordenPharma
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Siegfried Holding AG
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. oral solid dosage contract manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. oral solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 5 U.S. oral solid dosage contract manufacturing market, by mechanism, 2018 - 2030 (USD Million)
  • Table 6 U.S. oral solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. oral solid dosage contract manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and mechanism outlook (USD Million)
  • Fig. 10 End use outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. oral solid dosage contract manufacturing market dynamics
  • Fig. 13 U.S. oral solid dosage contract manufacturing market: Porter's five forces analysis
  • Fig. 14 U.S. oral solid dosage contract manufacturing market: PESTLE analysis
  • Fig. 15 U.S. oral solid dosage contract manufacturing market: Product segment dashboard
  • Fig. 16 U.S. oral solid dosage contract manufacturing market: Product market share analysis, 2024 & 2030
  • Fig. 17 Tablets market, 2018 - 2030 (USD Million)
  • Fig. 18 Capsules market, 2018 - 2030 (USD Million)
  • Fig. 19 Powders market, 2018 - 2030 (USD Million)
  • Fig. 20 Granules market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. oral solid dosage contract manufacturing market: Mechanism segment dashboard
  • Fig. 23 U.S. oral solid dosage contract manufacturing market: Mechanism market share analysis, 2024 & 2030
  • Fig. 24 Immediate release market, 2018 - 2030 (USD Million)
  • Fig. 25 Delayed release market, 2018 - 2030 (USD Million)
  • Fig. 26 Controlled release market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. oral solid dosage contract manufacturing market: End use segment dashboard
  • Fig. 28 U.S. oral solid dosage contract manufacturing market: End use market share analysis, 2024 & 2030
  • Fig. 29 Large size companies market, 2018 - 2030 (USD Million)
  • Fig. 30 Medium & small size companies market, 2018 - 2030 (USD Million)
  • Fig. 31 Others market, 2018 - 2030 (USD Million)
  • Fig. 32 Company categorization
  • Fig. 33 Company market position analysis
  • Fig. 34 Strategic framework